- Home
- ANIX vs CGO Comparison
ANIX vs CGO Comparison
Compare ANIX & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANIX | CGO |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 112.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | CGO |
|---|---|---|
| Price | $2.95 | $12.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 141.7K | 27.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.25% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $8.71 |
| 52 Week High | $5.46 | $12.79 |
Technical Indicators
Market Signals| Indicator | ANIX | CGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 62.64 |
| Support Level | $2.69 | $11.40 |
| Resistance Level | $3.00 | N/A |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 70.42 | 73.77 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.